M Maio|G Parmiani - JoVE Visualize

Showing results (241-250 of 317) with videos related to

Pageof 32

Sort By:

The Journal of Experimental Medicine|August 1, 1996

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)D J Loftus, C Castelli, T M Clay, et al.

Folia Biologica|January 1, 1996

Cytokine-based gene therapy of human tumors. An overviewG Parmiani, F Arienti, J Sulé-Suso, et al.

Cytokine|May 1, 1997

Biphasic control of NF-kappa B activation induced by the triggering of HLA-DR antigens expressed on B cellsA Leonardi, M Altomonte, M Maio, et al.

Human Gene Therapy|September 1, 1994

Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytesF Arienti, J Sulé-Suso, C Melani, et al.

Cancer Research|July 15, 1993

Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cellsM Altomonte, A Gloghini, G Bertola, et al.

Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1996

Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytesA Mazzocchi, W J Storkus, C Traversari, et al.

The Journal of Experimental Medicine|September 8, 1999

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesionsA Anichini, A Molla, R Mortarini, et al.

The Journal of Clinical Investigation|October 1, 1996

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigenM J Maeurer, S M Gollin, D Martin, et al.

Cancer Research|October 1, 1985

Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virusG Carbone, M A Pierotti, M Boiocchi, et al.

Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapyL Rivoltini, D J Loftus, K Barracchini, et al.

Pageof 32

Showing results (241-250 of 317) with videos related to

Sort By:

Pageof 32

The Journal of Experimental Medicine|August 1, 1996

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)D J Loftus, C Castelli, T M Clay, et al.

Folia Biologica|January 1, 1996

Cytokine-based gene therapy of human tumors. An overviewG Parmiani, F Arienti, J Sulé-Suso, et al.

Cytokine|May 1, 1997

Biphasic control of NF-kappa B activation induced by the triggering of HLA-DR antigens expressed on B cellsA Leonardi, M Altomonte, M Maio, et al.

Human Gene Therapy|September 1, 1994

Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytesF Arienti, J Sulé-Suso, C Melani, et al.

Cancer Research|July 15, 1993

Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cellsM Altomonte, A Gloghini, G Bertola, et al.

Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1996

Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytesA Mazzocchi, W J Storkus, C Traversari, et al.

The Journal of Experimental Medicine|September 8, 1999

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesionsA Anichini, A Molla, R Mortarini, et al.

The Journal of Clinical Investigation|October 1, 1996

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigenM J Maeurer, S M Gollin, D Martin, et al.

Cancer Research|October 1, 1985

Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virusG Carbone, M A Pierotti, M Boiocchi, et al.

Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1996

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapyL Rivoltini, D J Loftus, K Barracchini, et al.

Pageof 32